Anlon Healthcare IPO GMP Today

GMP for Anlon Healthcare IPO started at Rs 0 on 21 August 2025 and stood at Rs 2 on 1 September 2025. The sharpest single-day jump was from Rs 0 on 24 Aug 2025 to Rs 5 on 25 Aug 2025. GMP has moved in both directions during the tracked period. That often means sentiment is unsettled and the final listing price is harder to predict.

Based on today's GMP, Anlon Healthcare IPO listing price estimate is Rs 92.00 per share (issue price Rs 91.00 + GMP Rs 1.00).

Actual listing price will be known on 3 September 2025 when the stock lists on NSE/BSE.

GMP near 1.1% is a weak positive signal. Grey market activity is thin and the listing premium may be limited unless subscription picks up.

GMP is unofficial. Listing gain can differ on listing day.

GMP and subscription numbers often move together. When institutional and HNI demand is strong, grey market participants usually price in a higher premium. Current overall subscription for Anlon Healthcare IPO is 7.12x. Compare this with the GMP trend to see if demand aligns. The GMP move around 25 Aug 2025 may reflect how the market reacted once the subscription window activity picked up after 26 Aug 2025.

See live figures on the Anlon Healthcare IPO Subscription Status page.

Anlon Healthcare IPO full details (financials, peers, review).

Anlon Healthcare is a chemical manufacturing company engaged in the production of high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs). These products are used as raw materials in various finished dosages like tablets, capsules, ointments, and syrups, as well as in nutraceuticals, personal care, and veterinary products. The company is one of the few domestic manufacturers of loxoprofen sodium dihydrate, a key ingredient for pain and inflammation treatment. It has 65 commercialized products, with a robust pipeline of 28 products at the pilot stage and 49 products under lab testing. Anlon has a manufacturing facility in Rajkot, Gujarat, which is equipped with an installed capacity of 400 MTPA and four in-house laboratories. The company has received Drug Master File (DMF) approvals from regulatory bodies in Brazil, China, and Japan, which enhances its export potential.